# A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

> **NCT03417102** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 60 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** fitusiran
- **DRUG:** Bypassing agents

## Key facts

- **NCT ID:** NCT03417102
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-14
- **Primary completion:** 2020-11-25
- **Final completion:** 2021-06-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417102, "A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03417102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*